Literature DB >> 4857604

Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative.

J Maj, H Sowińska, L Baran, J Sarnek.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4857604     DOI: 10.1016/0014-2999(74)90067-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


× No keyword cloud information.
  7 in total

1.  In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson.

Authors:  W Wesemann; G Dette-Wildenhahn; H Fellehner
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

2.  Antiparkinsonian effect of flupirtine in monoamine-depleted rats.

Authors:  M Schwarz; M Nolden-Koch; J Purr; G Pergande; F Block
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats.

Authors:  W Löscher; D Hönack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-05       Impact factor: 3.000

4.  The reduction of excitability of the gamma-loop by 1,3-dimethyl-5-aminoadamantane (DMAA).

Authors:  K H Sontag; P Wand; H Cremer; B Mühlberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

5.  Anticonvulsant action of 1,3-dimethyl-5-aminoadamantane. Pharmacological studies in rodents and baboon, Papio papio.

Authors:  B S Meldrum; L Turski; M Schwarz; S J Czuczwar; K H Sontag
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

6.  Modulation of NMDA effects on agonist-stimulated phosphoinositide turnover by memantine in neonatal rat cerebral cortex.

Authors:  R Mistry; R Wilke; R A Challiss
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

Review 7.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.